BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1079 related articles for article (PubMed ID: 25925381)

  • 21. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of the JAX Cancer Treatment Profileā„¢ for detection of clinically actionable mutations in solid tumors.
    Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
    Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.
    Chevrier S; Arnould L; Ghiringhelli F; Coudert B; Fumoleau P; Boidot R
    Int J Oncol; 2014 Sep; 45(3):1167-74. PubMed ID: 24990411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.
    Lin MT; Mosier SL; Thiess M; Beierl KF; Debeljak M; Tseng LH; Chen G; Yegnasubramanian S; Ho H; Cope L; Wheelan SJ; Gocke CD; Eshleman JR
    Am J Clin Pathol; 2014 Jun; 141(6):856-66. PubMed ID: 24838331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
    Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
    Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
    Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N
    Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of somatic mutations in tumors using unaligned clonal sequencing data.
    Sutton KM; Crinnion LA; Wallace D; Harrison S; Roberts P; Watson CM; Markham AF; Bonthron DT; Quirke P; Carr IM
    Lab Invest; 2014 Oct; 94(10):1173-83. PubMed ID: 25068661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience.
    Gurav M; Epari S; Gogte P; Pai T; Deshpande G; Karnik N; Shetty O; Desai S
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7413-7425. PubMed ID: 36935431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
    Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
    Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests.
    Angulo B; Lopez-Rios F; Gonzalez D
    Expert Rev Mol Diagn; 2014 Jun; 14(5):517-24. PubMed ID: 24844134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of an NGS mutation detection panel for melanoma.
    Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
    BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
    Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
    Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
    Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
    J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
    Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
    Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.